Drug Combination Details
| General Information of the Combination (ID: C37715) | |||||
|---|---|---|---|---|---|
| Name | Arsenic trioxide NP Info | + | Androgen Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Prostate cancer
[ICD-11: 2C82]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Down-regulation | Phosphorylation | AKT1 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Expression | ATG5 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Cleavage | CASP3 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Phosphorylation | CYB5R2 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | MAP1LC3A | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Phosphorylation | mTOR | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Cleavage | PARP1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Phosphorylation | S6K1 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | SQSTM1 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | LNCaP | CVCL_0395 | Prostate carcinoma | Homo sapiens | ||
| PC-3 | CVCL_0035 | Prostate carcinoma | Homo sapiens | |||
| Experimental
Result(s) |
Arsenic trioxide enhances the radiation sensitivity of androgen-dependent and -independent human prostate cancer cells. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Arsenic trioxide enhances the radiation sensitivity of androgen-dependent and -independent human prostate cancer cells. PLoS One. 2012;7(2):e31579. | |||
